The Basel-based pharmaceuticals company, Roche, has formed an alliance with the US Millennium group to develop diagnostic products for rheumatoid arthritis.
Under the three-year deal, Millennium will receive a licensing fee, royalties and funding for research. Roche gets certain research and development rights and will market products resulting from the alliance.
"The combination of Roche's world-class strength in diagnostics with Millennium's strong position in genomics and proteomics will bring revolutionary diagnostic products to the market," said Heino von Prondzynski, the head of Roche's diagnostics division.
No financial details of the agreement have been released.
Swissinfo with agencies